Pregled bibliografske jedinice broj: 710792
Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen : case report
Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen : case report // World journal of surgical oncology, 12 (2014), 264-1 doi:10.1186/1477-7819-12-264 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 710792 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen : case report
Autori
Dedić Plavetić, Natalija ; Rakušić, Zoran ; Ozretić, David ; Simetić, Luka ; Mišir Krpan, Ana ; Bišof, Vesna
Izvornik
World journal of surgical oncology (1477-7819) 12
(2014);
264-1
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
chemotherapy; fluoropyrimidine; fluorouracil; irinotecan; posterior reversible encephalopathy syndrome
Sažetak
Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity characterized by headaches, altered mental status, seizures, and visual disturbances. It can occur in many different clinical entities such as severe hypertension and pre-eclampsia, or due to cytotoxic or immunosuppressive therapies. The pathogenesis of PRES is unclear, with dysregulated cerebral auto-regulation and endothelial dysfunction as important mechanisms proposed. Endothelial dysfunction is important especially in cases associated with cytotoxic therapies. Herein, we describe a patient with PRES with fatal outcome, who presented 5 days after the infusion of cycle 1 of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy, without prior hypertension and other comorbidity, suggesting a link between PRES and FOLFIRI regimen. To our knowledge, this case report is the first describing PRES after FOLFIRI regimen, although others have described PRES after FOLFIRI with bevacizumab in colonic cancer patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Luka Simetić
(autor)
Vesna Bišof
(autor)
David Ozretić
(autor)
Natalija Dedić-Plavetić
(autor)
Ana Mišir Krpan
(autor)
Zoran Rakušić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE